In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $8.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason Zemansky has given his Buy rating due to a combination of factors, led by the U.S. FDA’s approval of Rocket’s gene therapy Kresladi for LAD‑I and the concurrent award of a valuable priority review voucher. He sees this approval not primarily as a near‑term earnings driver, but as an important strategic inflection point that helps reset the company’s story after prior clinical and regulatory setbacks.
At the same time, he acknowledges that investor skepticism and gene‑therapy class concerns persist, reflected in elevated short interest and the modest standalone sales outlook for Kresladi. Nonetheless, Zemansky believes that the Kresladi approval, potential PRV monetization, and future catalysts such as clarity on the Danon program together create an attractive risk‑reward profile, supporting his Buy rating and $8 price objective on RCKT shares.
Zemansky covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Cytokinetics, and Madrigal Pharmaceuticals. According to TipRanks, Zemansky has an average return of 23.4% and a 59.52% success rate on recommended stocks.